News

The Feinstein Institutes for Medical Research announced that the U.S. Food and Drug Administration (FDA) has approved an imaging compound its researchers developed as a diagnostic tool for people with suspected parkinsonian syndromes, including Parkinson’s disease. Fluorodopa F18 (FDOPA) is an injectable compound used during a PET…

Parkinson’s News Today keeps you up-to-date with research into Parkinson’s disease as it emerges. We brought you daily coverage of experiments into the basic biology of Parkinson’s, results of clinical and pre-clinical trials, and key findings from Parkinson’s research around the globe. We look forward to bringing more such…

A Phase 1 clinical trial of MODAG Neuroscience Solutions’ lead candidate anle138b is now underway and recruiting healthy participants at its one site in Nottingham, England, to study the compound’s safety. The small molecule is being developed to treat multiple system atrophy (MSA), but holds the potential to…

Gosuranemab failed to meet its primary and key secondary goals in a Phase 2 study evaluating its use in treating progressive supranuclear palsy, an atypical parkinsonian disorder, its developer, Biogen, has announced. Based on these results, Biogen will cease the clinical development of gosuranemab for this and other neurodegenerative diseases…

Sprint running is a safe and feasible form of physical exercise for people with mild-to-moderate Parkinson’s disease. That is the conclusion reached in the study, “Sprint exercise for subjects with mild-to-moderate Parkinson’s disease: Feasibility and biomechanical outputs,” was published in Clinical Biomechanics. Physical exercise has been…

Interactive sessions, including games that are intended to help elderly Parkinson’s patients learn strategies to avoid falling, are well-received, a small Brazilian study suggests. The study, “Gerontotechnology for fall prevention of the elderly with Parkinson,” was published recently in Revista Brasileira de Enfermagem.  Falling is a major…